{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:29:13Z","timestamp":1789723753794,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11060-017-2533-6","type":"journal-article","created":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T02:32:48Z","timestamp":1498876368000},"page":"357-362","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study"],"prefix":"10.1007","volume":"134","author":[{"given":"Andrew","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Faiq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jethro","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy F.","family":"Cloughesy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Mellinghoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Leia","family":"Nghiemphu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,1]]},"reference":[{"key":"2533_CR1","doi-asserted-by":"publisher","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","volume":"17","author":"T Quinn","year":"2015","unstructured":"Quinn T, Ostrom HG, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2015) CBTRUS Statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012. Neuro Oncol 17:iv1\u2013iv62","journal-title":"Neuro Oncol"},{"key":"2533_CR2","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987\u2013996","journal-title":"N Engl J Med"},{"key":"2533_CR3","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1093\/neuonc\/nox014","volume":"19","author":"TF Cloughesy","year":"2017","unstructured":"Cloughesy TF, Lassman AB (2017) NovoTTF: where to go from here? Neuro-oncol 19:605\u2013608","journal-title":"Neuro-oncol"},{"key":"2533_CR4","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","volume":"155","author":"CW Brennan","year":"2013","unstructured":"Brennan CW, Verhaak RG, McKenna A et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462\u2013477","journal-title":"Cell"},{"key":"2533_CR5","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/S0360-3016(01)01609-1","volume":"51","author":"FG Barker 2nd","year":"2001","unstructured":"Barker FG 2nd, Simmons ML, Chang SM et al (2001) EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 51:410\u2013418","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2533_CR6","doi-asserted-by":"publisher","first-page":"4252","DOI":"10.1158\/0008-5472.CAN-08-4853","volume":"69","author":"B Mukherjee","year":"2009","unstructured":"Mukherjee B, McEllin B, Camacho CV et al (2009) EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 69:4252\u20134259","journal-title":"Cancer Res"},{"key":"2533_CR7","first-page":"5079","volume":"56","author":"M Nagane","year":"1996","unstructured":"Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK, Huang HJ (1996) A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56:5079\u20135086","journal-title":"Cancer Res"},{"key":"2533_CR8","first-page":"6962","volume":"63","author":"N Shinojima","year":"2003","unstructured":"Shinojima N, Tada K, Shiraishi S et al (2003) Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63:6962\u20136970","journal-title":"Cancer Res"},{"key":"2533_CR9","doi-asserted-by":"publisher","first-page":"5603","DOI":"10.1200\/JCO.2008.18.0612","volume":"26","author":"PD Brown","year":"2008","unstructured":"Brown PD, Krishnan S, Sarkaria JN et al (2008) Phase I\/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. J Clin Oncol 26:5603\u20135609","journal-title":"J Clin Oncol"},{"key":"2533_CR10","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2008.18.9639","volume":"27","author":"MD Prados","year":"2009","unstructured":"Prados MD, Chang SM, Butowski N et al (2009) Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma. J Clin Oncol 27:579\u2013584","journal-title":"J Clin Oncol"},{"key":"2533_CR11","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11060-009-0067-2","volume":"98","author":"DM Peereboom","year":"2010","unstructured":"Peereboom DM, Shepard DR, Ahluwalia MS et al (2010) Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme. J Neurooncol 98:93\u201399","journal-title":"J Neurooncol"},{"key":"2533_CR12","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/neuonc\/nop015","volume":"12","author":"JJ Raizer","year":"2010","unstructured":"Raizer JJ, Abrey LE, Lassman AB et al (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro-oncol 12:95\u2013103","journal-title":"Neuro-oncol"},{"key":"2533_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1158\/2159-8290.CD-11-0284","volume":"2","author":"I Vivanco","year":"2012","unstructured":"Vivanco I, Robins HI, Rohle D et al (2012) Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov 2:458\u2013471","journal-title":"Cancer Discov"},{"key":"2533_CR14","doi-asserted-by":"publisher","first-page":"5569","DOI":"10.1158\/1078-0432.CCR-09-0522","volume":"15","author":"AJ Chien","year":"2009","unstructured":"Chien AJ, Illi JA, Ko AH et al (2009) A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res 15:5569\u20135575","journal-title":"Clin Cancer Res"},{"key":"2533_CR15","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3171\/jns.1977.47.3.0329","volume":"47","author":"VA Levin","year":"1977","unstructured":"Levin VA, Crafts DC, Norman DM, Hoffer PB, Spire JP, Wilson CB (1977) Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. J Neurosurg 47:329\u2013335","journal-title":"J Neurosurg"},{"key":"2533_CR16","unstructured":"Institute NC (2009). Common Terminology Criteria for Adverse Events v4.0. NIH publication # 09-7473"},{"key":"2533_CR17","volume-title":"2016 Physicians\u2019 Desk Reference","author":"Reference PD","year":"2015","unstructured":"Reference PD (2015) 2016 Physicians\u2019 Desk Reference.PDR Network, LLC, Montvale"},{"key":"2533_CR18","doi-asserted-by":"publisher","first-page":"4085","DOI":"10.1200\/JCO.2013.49.6968","volume":"31","author":"MR Gilbert","year":"2013","unstructured":"Gilbert MR, Wang M, Aldape KD et al (2013) Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 31:4085\u20134091","journal-title":"J Clin Oncol"},{"key":"2533_CR19","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1007\/s00415-012-6812-z","volume":"260","author":"V Karavasilis","year":"2013","unstructured":"Karavasilis V, Kotoula V, Pentheroudakis G et al (2013) A phase I study of temozolomide and lapatinib combination in patients with recurrent high-grade gliomas. J Neurol 260:1469\u20131480","journal-title":"J Neurol"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11060-017-2533-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-017-2533-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T10:27:34Z","timestamp":1628591254000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11060-017-2533-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,1]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["2533"],"URL":"https:\/\/doi.org\/10.1007\/s11060-017-2533-6","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,1]]},"assertion":[{"value":"13 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors do not declare any conflicts of interest related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}